{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:44:10Z","timestamp":1791211450030,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":86,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacepopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACEP Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1002\/emp2.13338","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:04:41Z","timestamp":1729749881000},"page":"e13338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010\u20122017)"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-4055","authenticated-orcid":false,"given":"Karilynn M.","family":"Rockhill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle E.","family":"Bau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"DeVeaugh\u2010Geiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Chilcoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janetta","family":"Iwanicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1002\/emp2.13338_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20122019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1002\/emp2.13338_bb0015","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and Opioid\u2010Involved Overdose Deaths\u2014United States, 2013\u20122017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1002\/emp2.13338_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1002\/emp2.13338_bb0025","unstructured":"Code of Federal Regulations. Medication Assisted Treatment for Opioid Use Disorders. Substance Abuse and Mental Health Services Administration (SAMHSA), HHS. 42 CFR 8. 2016."},{"key":"10.1002\/emp2.13338_bb0030","unstructured":"Milgram A. DEA Announced Important Change to Registration Requirement. US Department of Justice. October 9, 2023 [updated January 12, 2023]. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A\u201023\u20100020\u2010Dear\u2010Registrant\u2010Letter\u2010Signed.pdf"},{"key":"10.1002\/emp2.13338_bb0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"10.1002\/emp2.13338_bb0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156973","article-title":"Modeling buprenorphine reduction of fentanyl\u2010induced respiratory depression","volume":"7","author":"Olofsen","year":"2022","journal-title":"JCI Insight"},{"issue":"6","key":"10.1002\/emp2.13338_bb0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1002\/emp2.13338_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","article-title":"Mechanism\u2010based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers","volume":"81","author":"Yassen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/emp2.13338_bb0055","unstructured":"National Vital Statistics System. Instructions for classifying the underlying cause of death. NCHS Instruction Manual: Part 2a. National Center for Health Statistics."},{"issue":"03","key":"10.1002\/emp2.13338_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-0495.1000164","article-title":"Defining controlled substances overdose: should deaths from substance use disorders and pharmaceutical adverse events be included?","volume":"03","author":"Dasgupta","year":"2013","journal-title":"J Clin Toxicol"},{"key":"10.1002\/emp2.13338_bb0065","unstructured":"Vermont Department of Health. Opioid\u2010Related Fatalities Among Vermonters. Burlington, VT: Vermont Department of Health; 2020. https:\/\/www.healthvermont.gov\/sites\/default\/files\/documents\/pdf\/ADAP_Data_Brief_Opioid_Related_Fatalities.pdf"},{"issue":"9","key":"10.1002\/emp2.13338_bb0070","first-page":"1","article-title":"Using literal text from the death certificate to enhance mortality statistics: characterizing drug involvement in deaths","volume":"65","author":"Trinidad","year":"2016","journal-title":"Natl Vital Stat Rep"},{"issue":"172","key":"10.1002\/emp2.13338_bb0075","first-page":"1","article-title":"The validity of race and Hispanic\u2010origin reporting on death certificates in the United States: an update","volume":"2","author":"Arias","year":"2016","journal-title":"Vital Health Stat"},{"issue":"3","key":"10.1002\/emp2.13338_bb0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"issue":"19","key":"10.1002\/emp2.13338_bb0085","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/sim.7344","article-title":"Improved confidence interval for average annual percent change in trend analysis","volume":"36","author":"Kim","year":"2017","journal-title":"Stat Med"},{"issue":"29","key":"10.1002\/emp2.13338_bb0090","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/sim.3733","article-title":"Estimating average annual per cent change in trend analysis","volume":"28","author":"Clegg","year":"2009","journal-title":"Stat Med"},{"key":"10.1002\/emp2.13338_bb0095","unstructured":"Joinpoint Regression Program. Statistical Research and Applications Branch. Version 4.9.0.0. National Cancer Institute; 2021."},{"issue":"1","key":"10.1002\/emp2.13338_bb0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13181-013-0323-x","article-title":"Complete republication: National Association of Medical Examiners position paper: recommendations for the investigation, diagnosis, and certification of deaths related to opioid drugs","volume":"10","author":"Davis","year":"2014","journal-title":"J Med Toxicol"},{"key":"10.1002\/emp2.13338_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109933","article-title":"Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016\u20122021","volume":"248","author":"Larochelle","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1002\/emp2.13338_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","article-title":"The relationship between diversion\u2010related attitudes and sharing and selling buprenorphine","volume":"78","author":"Kenney","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"21","key":"10.1002\/emp2.13338_bb0115","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/jama.2021.4469","article-title":"Concentration of patient care among buprenorphine\u2010prescribing clinicians in the US","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/emp2.13338_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long\u2010acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J Addict Med"},{"issue":"5","key":"10.1002\/emp2.13338_bb0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/emp2.13338_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1002\/emp2.13338_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130100920","article-title":"Blockade of hydromorphone effects by buprenorphine\/naloxone and buprenorphine","volume":"159","author":"Strain","year":"2002","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/emp2.13338_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256752","article-title":"Effect of sustained high buprenorphine plasma concentrations on fentanyl\u2010induced respiratory depression: a placebo\u2010controlled crossover study in healthy volunteers and opioid\u2010tolerant patients","volume":"17","author":"Moss","year":"2022","journal-title":"PLoS One"},{"issue":"17","key":"10.1002\/emp2.13338_bb0145","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010\u20122016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/emp2.13338_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.51856","article-title":"Trends and characteristics of buprenorphine\u2010involved overdose deaths prior to and during the COVID\u201019 pandemic","volume":"6","author":"Tanz","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1002\/emp2.13338_bb0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1002\/emp2.13338_bb0160","first-page":"313","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1002\/emp2.13338_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.annepidem.2022.03.011","article-title":"Clustering patterns in polysubstance mortality in the United States in 2017: a multiple correspondence analysis of death certificate data","volume":"77","author":"Black","year":"2023","journal-title":"Ann Epidemiol"}],"container-title":["JACEP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224014875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224014875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/emp2.13338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:28:38Z","timestamp":1738754918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2688115224014875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2688115224014875"],"URL":"https:\/\/doi.org\/10.1002\/emp2.13338","relation":{},"ISSN":["2688-1152"],"issn-type":[{"value":"2688-1152","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010\u20122017)","name":"articletitle","label":"Article Title"},{"value":"JACEP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/emp2.13338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e13338"}}